ALX Oncology Inc.

ALXO | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.66

-$0.04 (-2.35%)

At close: Sep 21, 2026, 4:00 PM ET

$1.65

-$0.01 (-0.60%)

After-hours: Sep 21, 2026, 7:52 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.35%

(1D)

Rating

Updated: Aug 27, 2026

21.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $223.37M

1D Range

1.65 1.72

52W Range

1.05 2.66

Valuation (TTM)

PE -1.29

PB 1.64

EV/EBITDA -1.19

Valuation (NTM)

Forward PE N/A

Forward PEG 0.67

Price Target $17.90

Cash Flow

FCF Yield -40.1%

SBC Adj. FCF Yield -45.9%

SBC Impact -14.4%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 49.4% | 14.6%

FCF 3Y | 5Y 20.4% | 0.1%

Returns

ROA -50.3%

ROE -90.3%

ROIC -56.5%

Financial Health

Net Cash

$128.52M

Current Ratio 9.71

Interest Coverage -58.67

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD...

Sector Healthcare

Industry Biotechnology

Employees 48

IPO Date Jul 16, 2020

Website www.alxoncology.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$21

Upside

+1165.06%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞